G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Web Exclusive How Antiobesity Drugs Are Linked to Food Waste. Taking antiobesity drugs has led some US adults to throw away more food than they tossed before starting the medicati ...

In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

Nascent research into the link between gut health and brain function and the rise of GLP-1 weight-loss drugs could aid the growth of a category of products that's spreading from dairy and into ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College ...